Subscribe To
Ethernity networks ltd make progress with major fibre controller contract
Ethernity Networks Ltd (AIM:ENET, OTCQB:ENETF), a company that provides data processing semiconductor technology for networking appliances, has given ...
March 6, 2023, 3:12 am
Ready capital saves broadmark realty from collapse
Ready Capital is merging with Broadmark Realty in an all-share transaction that will see Broadmark's shareholders receive 0.47233 shares of Ready Capi...
March 5, 2023, 11:36 pm
Immuneering presents preclinical data with lead program imm-1-104 supporting universal-ras activity
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-...
March 5, 2023, 11:30 pm
Ron desantis attacks liberals in california speech as he mulls white house run
By Tim Reid SIMI VALLEY, CA (Reuters) – Republican Florida Governor Ron DeSantis took his fight against liberalism deep into the Democratic territor...
March 5, 2023, 11:06 pm
Amazon to close 8 of its cashierless go convenience stores
Amazon.com Inc. will close eight of its cashierless convenience stores as part of a broader plan to slash costs....
March 5, 2023, 9:44 pm
Another norfolk southern train derails in ohio, railroad says no toxins aboard
(Reuters) – Another train operated by the Norfolk Southern railroad company derailed in Ohio on Saturday, prompting local officials to order residen...
March 5, 2023, 2:54 pm
Petco health and wellness company: still appealing despite the market's reaction
Petco Health and Wellness Company has not fared all that well compared to the broader market. This comes even as sales continue to climb and as bottom...
March 5, 2023, 12:48 pm
Colgate-palmolive: a great choice for income investors, why i'm buying the dip
Colgate-Palmolive (along with most of the Consumer Staples sector) has underperformed the broader U.S. equity market this year. The company now trades...
March 5, 2023, 11:30 am
Silk road medical: today best nearby cap-gain medical equipment stock prospect
“A 3-5 month prospect from here of SILK share prices could reasonably range from a $47.07 low to a $61.27 high from its $47.29 present price, a gain...
March 5, 2023, 10:45 am
Sret: poor tradeability metrics, ongoing relative weakness, avoid for now
Global interest rates have been marching higher, and that has negatively impacted many yield-sensitive niches. High-dividend REITs are an area underpe...
March 5, 2023, 7:11 am
3 growth stocks with massive potential in the electric vehicle market
As we take big strides toward a cleaner and greener Earth, we will continue to see a lot of Electric Vehicles (EVs) on the...
March 5, 2023, 7:07 am
Iwf: recession fear will trigger another selloff
IWF owns a portfolio of U.S. large-cap growth stocks picked from the Russell 1000 index. The fund underperformed in 2022 but should outperform the bro...
March 5, 2023, 3:48 am
Another norfolk southern train derails in ohio; company says no toxins aboard
(Reuters) – Another train operated by the Norfolk Southern railroad company derailed in Ohio on Saturday, prompting local officials to order residen...
March 5, 2023, 1:51 am
With only 3% of total traded volume, is social trading "dead?”
The Social Trading concept was introduced for the first time over a decade ago, in 2008. It quickly gained popularity among many retail traders and...
March 4, 2023, 8:02 pm
What is the best lithium stock to buy now? our 7 top picks.
The lithium story is only set to accelerate. For the world to meet its climate goals and put millions of electric vehicles on the...
March 4, 2023, 7:21 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...
March 4, 2023, 3:30 pm